volume 34, issue 1, P35-43 2000
DOI: 10.1016/s0022-3956(99)00031-x
View full text
|
|
Share
Franz X Vollenweider, Peter Vontobel, Ivar Øye, Daniel Hell, Klaus L Leenders

Abstract: Administration of the N-methyl-D-aspartate (NMDA) antagonist S-ketamine in normals produces a psychosis-like syndrome including several positive and negative symptoms of schizophrenic disorders (Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998;31:104-109). Given the clinical efficacy of dopamine (DA) D2 receptor antagonists in the treatment of positive symptoms, it is conceivable that S-ketamine-induced psychotic sympto…

expand abstract